FDAnews
www.fdanews.com/articles/97023-nice-responds-to-court-rsquo-s-decision-on-alzheimer-rsquo-s-recommendations

NICE Responds to Court’s Decision on Alzheimer’s Recommendations

August 10, 2007

The UK’s National Institute for Health and Clinical Excellence (NICE) responded to a recent court decision in favor of the agency’s decision to fund certain Alzheimer’s drugs only for those in the moderate stage of the disease.

According to Andrew Dillon, NICE’s chief executive, the agency’s funding decision was challenged on six grounds, and the court found in the agency’s favor on five of them.

According to NICE, the judge said the agency had breached its duties under the Disability Discrimination Act and the Race Relations Act by not offering specific advice regarding people with learning disabilities and people for whom English is not their first language in its technology appraisal guidance.

Dillon said the agency will reissue the guidance to the National Health Service to clarify this issue.